Notice Regarding Transition to a Company with an Audit and Supervisory Committee
Filed with TSE · · 1 page · English
On 6ix: 6ix.com/news/notice-regarding-transition-to-a-company-with-an-audit-and-supervisory-committee
Otsuka Holdings Co., Ltd. on 6ix
Earlier from Otsuka
- Otsuka Presents Final Phase 3 VISIONARY Results for VOYXACT at ASN
- Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.
- NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR Program
- Notice regarding the status of share repurchases
- Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Later from Otsuka
All Otsuka news releasesFollow Otsuka into a list and get an email when it puts out news.
Follow Otsuka